• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Can Copper and Levonorgestrel IUD Use Be Safely Extended?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Ti et al. (AJOG, 2020) assessed whether extended use of copper (Cu) and levonorgestrel (LNG) IUDs is safe and effective

METHODS:

  • Systematic review and meta-analysis (from inception through June 2019)
  • Data sources
    • PubMed | Embase | Cumulative Index to Nursing and Allied Health Literature | Global Index Medicus
  • Study inclusion criteria
    • RCTs, cohort (comparative and noncomparative) studies, and case-control studies
    • Women using modern T380A copper or levonorgestrel IUDs (52 mg, 18.5 mg, and 13.5 mg) past their approved duration date
  • Data analysis
    • Study quality was assessed for risk of bias, precision, and external validity
    • Pooled pregnancy rate during the first 2 years of extended use for each intrauterine device type was calculated
  • Primary outcome
    • Pregnancy among extended use cohort
  • Safety outcomes
    • Adverse events: Expulsion | Displacement | Perforation | Infection
    • Side effects: Bleeding and pain sufficient to require discontinuation during extended use time frame

RESULTS:

  • 6 studies were included
    • Levonorgestrel IUD (52 mg): 4 studies (approved for 5 years)
      • Studies were assessed as good-to-poor-quality | 2098 women were included
    • T380A copper IUD: 2 studies (approved for 10 years)
      • Studies were assessed as good-to-fair-quality | 245 women were included

Primary Outcome: Pregnancy

  • Levonorgestrel IUD
    • Pooled pregnancy rates
      • Year 6: 0.02 per 100 person-years (95% CI, 0.00 to 0.45)
      • Year 7: 0.03 per 100 person-years (95% CI, 0.00 to 0.71)
      • Years 6 and 7 combined: 0.02 per 100 person-years (95% CI, 0.00 to 0.29)
    • Adverse events or discontinuation during extended period
      • Annual rates: 0 to 3.7 per 100 participants
  • Copper IUD
    • Pooled pregnancy rates
      • Years 11 and 12
        • 0.0 per 100 person-years (95% CI, 0.0 to 0.8)
    • Adverse events or discontinuation during extended period
      • Annual rates: 0 to 4.6 per 100 participants

CONCLUSION:

  • Pregnancy rates and adverse outcomes during 2 years of extended levonorgestrel or copper IUD use are similar to those seen during approved length of use
  • The authors caution that the data were limited in quality and quantity, and that these results may not be generalizable to all IUD users
  • The appropriate RCT design to answer the question posed in this study would be to randomize patients as they come to the end of approved length of use to either retention or a new IUD
  • However, the authors also state that  

…absent more definitive research, clinicians can help patients balance the existing data with individual concerns and circumstances, including the patient’s medical history, access to care, and the potential impact of IUD failure

Learn More – Primary Sources:

Effectiveness and safety of extending intrauterine device duration: a systematic review

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Outcomes after Immediate Postpartum IUD Insertion
IUDs, Lower Cervical Cancer Rates and HPV – Is There a Connection?
Can 1% Lidocaine Reduce Pain During IUD Insertion in Nulliparous Women?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site